— Why it moved
Why CNTB Stock Spiked and Faded Today — September 30, 2026
Connect Biopharma posted positive Phase 2 trial results before the session's start, but a brief premarket pop gave way to heavy selling.
What moved CNTB stock
Connect Biopharma is a clinical-stage biotech developing therapies for inflammatory diseases. The company reported positive Phase 2 trial data for its COPD candidate rademikibart early in the day. While the numbers looked clean on paper, an analyst price target cut and immediate profit-taking squashed the initial excitement.
The mechanics
A 21.5 million share float traded more than 165 million shares throughout the session. That staggering turnover turned an early 68 percent gap into an exit ramp for existing positions.
CNTB by the numbers
The alert window
The alert hit at 7:56 AM at $1.74. It took ten minutes to reach the $2.08 peak, giving a fast 19.5 percent window after enduring a quick slide to $1.69. If you did not take profits in premarket, the stock spend the next nine hours bleeding out.
How CNTB's move ended
CNTB closed at $1.10, dumping 36.8 percent below the alert price. Mid-stage trial headlines sound great, but microcap biotechs usually use these high-volume spikes to absorb heavy selling pressure.
The tell: Premarket clinical trial spikes on cheap biotechs almost always peak before the regular session starts.